Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01403402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Study acronym: CMDPROS
StatusRecruiting
PhaseNot specified
SponsorCure CMD
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment target: 1000 to 4000
    • Primary and study completion dates: Sep 2019 to Sep 2029
    • Site details revised
    v12
  2. Minor Eligibility criteria expanded, about 140 words
    • Study description shortened, about 19 words
    • Site contact updated
    v11
  3. Minor Re-verified, no change to tracked fieldsv10
  4. Minor Site details revisedv9
  5. Minor 3 versions Re-verified since Feb 3, 2015, no change to tracked fieldsv6-v8
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study Status, Sponsor/Collaborators, Outcome Measuresv5
  2. Minor Site contact updatedv4
  3. Minor Study site revisedv3
  4. Minor Collaborators shortened, about 26 wordsv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
769 trials monitored
See 48 trials at risk
The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a longitudinal 10 year study to identify and trend care parameters, adverse events in the congenital muscle diseases using the Congenital Muscle Disease International Registry (CMDIR) to acquire necessary data for adverse event calculations (intake survey and medical records curation). To support this study and become a participant, we ask that you register in the CMDIR. You can do this by visiting www.cmdir.org. There is no travel required. The registry includes affected individuals with congenital muscular dystrophy, congenital myopathy, and congenital myasthenic syndrome and registers through the late onset spectrum for these disease groups. The CMDIR was created to identify the global congenital muscle disease population for the purpose of raising awareness, standards of care, clinical trials and in the future a treatment or cure. Simply put, we will not be successful in finding a treatment or cure unless we know who the affected individuals are, what the diagnosis is and how the disease is affecting the individual. Registering in the CMDIR means that you will enter demographic information and complete an intake survey. We would then ask that you provide records regarding the diagnosis and treatment of CMD, including genetic testing, muscle biopsy, pulmonary function testing, sleep studies, clinic visit notes, and hospital discharge summaries. Study hypothesis: 1. To use patient and proxy reported survey answers and medical reports to build a longitudinal care and outcomes database across the congenital muscle diseases. 2. To generate congenital muscle disease subtype specific adverse event rates and correlate with key care parameters.
Trial Details
NCT Number NCT01403402
Lead Sponsor Cure CMD
Conditions
(from sponsor)
Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)), Alpha-Dystroglycanopathy (Fukuyama CMD), Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I)) +44 more
Related terms Epilepsy, Intellectual Disability, Muscular Dystrophies, Limb-Girdle, Muscular Dystrophy, Congenital, Due To Integrin Alpha-7 Deficiency, Muscular Dystrophy, Emery-Dreifuss, Muscular Dystrophy, Limb-Girdle, Type 2G, Muscular Dystrophy, Limb-Girdle, Type 2M, Musculoskeletal Diseases, Myasthenic Syndromes, Congenital, Myotonia Congenita, Neuromuscular Diseases, Walker-Warburg Syndrome, Wieacker syndrome
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov